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After the publication of this work \[[@CR1]\], we noticed that an incorrect version of Table two (Table [1](#Tab1){ref-type="table"} here) \[[@CR1]\] was published. The correct version of Table two (Table [1](#Tab1){ref-type="table"} here) is provided here.Table 1Current Ongoing trials for Prostate Cancer Oligometastases in 2014 ([www.clinicaltrials.gov](http://www.clinicaltrials.gov))StudyClinicalTrials.gov IdentifierPhaseAimArmsPrimary ObjetivesSecondary ObjetivesRadiotherapy for Oligometastatic Prostate CancerNCT018592212Efficacy and safety in patients with prymary active or not2: CR and HNImprovement in median progression-free survival in patients with metastatic prostate cancer over historic control rates in hormone receptive and castration resistant subgroups.Improvement in overall survival of patients with metastatic prostate cancer.University of FloridaTreatment failure rates in patients treated with stereotactic radiation for metastatic prostate cancer. after type of secondary outcome.Quality of life in patients treated with stereotactic radiation for metastatic prostate cancer.Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate CancerNCT022063341Safety Study1To determine the recommended SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting.I. To estimate rates of \> = grade 3 (CTCAE 4.0) adverse events other than a dose-limiting toxicity which is possibly, probably, or definitely related to treatment and which occurs within 6 months from the start of SBRT to multiple metastases.NRG Oncology Foundation, Inc.II. To estimate the rates of long-term adverse events occurring up to 2 years from the end of SBRT.Collaborator: NCI RTOGIII. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical structure definition, treatment planning, image guidance and delivery.Non-systemic Treatment for Patients With Low-volume Metastatic Prostate CancerNCT015584272Defer the start of ADT2: A. Active surveillanceAndrogen deprivation therapy free survival.Quality of lifeUniversity Hospital, GhentB. Surgical or radiotherapy treatment of metastasesPhase II Study of SBRT as Treatment for Oligometastases in Prostate CancerNCT021927882Safety and Efficacy Study1Local and symptomatic control of oligometastases treated by SBRTBiochemical progression ratesGICORProgression-free survival,Collaborators:Chemotherapy-free survival and overall survival.SBRT-SGAnalyze toxicities and quality of life of patients before and after treatmentSEORConsorcio Hospitalario Provincial de Castellón*CR* Castrate resistant, *HR* Hormone Receptive, *NCI* National Cancer Institut, *RTOG* Radiation Therapy Oncology Group, *ADT* androgen deprivation therapyCTCAE 4.0: Common Terminology Criteria for Adverse Events SBRT-SG: Sterotactic Body Radiation Therapy Spanish GroupGICOR: Spanish Group of clinical Investigation in Radiation Oncology SEOR: Spanish society of Radiation Oncology

The online version of the original article can be found under doi:10.1186/s13014-014-0258-7.
